Cartinex

Cartinex

ranolazine

Manufacturer:

Micro Labs

Distributor:

Zizawa Healthcare
Concise Prescribing Info
Contents
Ranolazine
Indications/Uses
Add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (eg, β-blockers &/or calcium antagonists).
Dosage/Direction for Use
Adult Initial dose: 500 mg bd. Max dose: 750 mg bd. Down-titrate to 375 mg bd if patient experiences adverse events (dizziness, nausea, vomiting).
Administration
May be taken with or without food: Swallow whole, do not break/chew/crush.
Contraindications
Hypersensitivity. Severe renal impairment (creatinine clearance <30 ml/min). Moderate or severe hepatic impairment. Concomitant administration of potent CYP3A4 inhibitors (eg, itraconazole, ketoconazole, voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone). Concomitant administration of Class Ia (eg, quinidine) or Class III (eg, dofetilide, sotalol) antiarrhythmics other than amiodarone.
Special Precautions
Concomitant administration of moderate CYP3A4 inhibitors & P-gp inhibitors. Mild hepatic impairment. Mild to moderate renal impairment (creatinine clearance 3,080 mL/min). Patients with low weight (60 kg). Patients with moderate to severe CHF (NYHA Class IIIIV). History of congenital or a family history of long QT interval prolongation, & in patients treated w/ drugs affecting the QTc interval. Pregnancy & lactation.
Adverse Reactions
Anorexia, decreased appetite, dehydration, anxiety, insomnia, dizziness, headache, blurred vision, visual disturbance, hot flush, hypotension, dyspnoea, cough, epistaxis, constipation, vomiting, nausea, abdominal pain, dry mouth, dyspepsia, flatulence, stomach discomfort, asthenia.
Drug Interactions
Increased plasma conc w/ CYP3A4 inhibitors (eg, itraconazole, ketoconazole, voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone), P-gp inhibitors (eg, ciclosporin, quinidine, verapamil), & CYP2D6 inhibitors. Increased plasma digoxin conc by an average of 1.5-fold. Possible risk of ventricular arrhythmias increased w/ drugs known to prolong the QTc interval eg, antiarrhythmics (eg, quinidine, disopyramide, procainamide), erythromycin & TCAs (eg, imipramine, doxepin, amitriptyline).
MIMS Class
Anti-Anginal Drugs
ATC Classification
C01EB18 - ranolazine ; Belongs to the class of other cardiac preparations.
Presentation/Packing
Form
Cartinex ER tab 500 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in